Phase III, multicenter, randomized, open-label study of oral asciminib versus an Investigator-selected tyrosine kinase inhibitor in patients with newly reported chronic phase Philadelphia chromosome-positive chronic myeloid leukemia.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: III
- Execution start: 18/10/2021
- End of execution: 30/11/2028
- IP: JOSE M PUERTA PUERTA